Qlaris Bio

Qlaris Bio is a private, clinical-stage biotech based in Cambridge, Massachusetts, advancing a novel mechanism for treating glaucoma and ocular hypertension. The company's core innovation targets episcleral venous pressure (EVP) to achieve intraocular pressure reduction beyond current standards of care. With its lead program QLS-111 in clinical development, Qlaris is positioned to address a significant unmet need in a large, chronic market. The company is led by an experienced team with deep ophthalmology and biotech expertise, supported by a strong scientific advisory board anchored by its academic founder.

Novel small molecule platform targeting episcleral venous pressure (EVP) to reduce distal outflow resistance and lower intraocular pressure (IOP), a previously untreatable component of IOP regulation.

Qlaris operates in the competitive glaucoma market, dominated by generic prostaglandin analogs. It faces competition from other novel IOP-lowering agents (e.g., Rho kinase inhibitors, nitric oxide donors) and a growing array of minimally invasive glaucoma surgical (MIGS) devices. Its key differentiator is the first-in-class approach to lowering episcleral venous pressure.